Head-to-head evidence
PMN310 vs Remternetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
PMN310
Developed by ProMIS Neurosciences, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06750432 (registry estimate)
Remternetug
Developed by Eli Lilly
NCT05463731 · Phase 3 · completed
The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.
Next expected readout: April 2029 · NCT06653153 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PMN310's landscape · Remternetug's landscape